Irritable bowel syndrome: A disease still searching for pathogenesis, diagnosis and therapy

World Journal of Gastroenterology

Volumn , Issue 27, 2014, Pages 8807-8820

  Bellini, Massimo ^a   Gambaccini, Dario ^a   Stasi, Cristina ^b,c   Urbano, Maria Teresa ^a   Marchi, Santino ^a   Usai Satta, Paolo ^d  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Health Agency of Tuscany Region   (Italy)

^d BROTZU HOSPITAL   (Italy)

Author keywords

Diagnosis; Irritable bowel syndrome; Pathogenesis; Therapy

Indexed keywords

ALOSETRON; AMITRIPTYLINE; CILANSETRON; CIMETROPIUM; COLESTYRAMINE; ELUXADOLINE; GASTRIC INHIBITORY POLYPEPTIDE; GLUTEN; ISPAGULA; LAXATIVE; LINACLOTIDE; LOPERAMIDE; LUBIPROSTONE; MACROGOL; MESALAZINE; NEOMYCIN; ONDANSETRON; OTILONIUM BROMIDE; PEPPERMINT OIL; PINAVERIUM; PROBIOTIC AGENT; PRUCALOPRIDE; RAMOSETRON; RIFAXIMIN; SCOPOLAMINE; SEROTONIN; SOMATOSTATIN; TEGASEROD; TRIMEBUTINE; UNINDEXED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; CARDIOVASCULAR DISEASE; CHINESE MEDICINE; CONSTIPATION; DIARRHEA; DIET; DIGITAL RECTAL EXAMINATION; DNA POLYMORPHISM; DOCTOR PATIENT RELATION; DROWSINESS; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; FATIGUE; FEVER; FOOD ALLERGY; GASTROESOPHAGEAL REFLUX; HEADACHE; HEREDITY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTESTINE INFECTION; INTESTINE PERFORATION; IRRITABLE COLON; ISCHEMIC COLITIS; LACTOSE INTOLERANCE; MALABSORPTION; MONOZYGOTIC TWINS; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL ABUSE; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; REVIEW; SEXUAL ABUSE; ULTRASOUND; UPPER RESPIRATORY TRACT INFECTION; URINE RETENTION; VISUAL DISORDER; WEIGHT REDUCTION; XEROSTOMIA; ANIMAL; IRRITABLE BOWEL SYNDROME; PREDICTIVE VALUE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANIMALS; HUMANS; IRRITABLE BOWEL SYNDROME; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84905365322     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i27.8807     Document Type: Review

References (111)

1. Bellini M, Tosetti C, Costa F, Biagi S, Stasi C, Del Punta A, Monicelli P, Mumolo MG, Ricchiuti A, Bruzzi P, Marchi S. The general practitioner's approach to irritable bowel syndrome: from intention to practice. Dig Liver Dis 2005; 37: 934-939 [PMID: 16243592 DOI: 10.1016/j.dld.2005.06.011]
2. Videlock EJ, Chang L. Irritable bowel syndrome: current approach to symptoms, evaluation, and treatment. Gastroenterol Clin North Am 2007; 36: 665-685, x [PMID: 17950443 DOI: 10.1016/j.gtc.2007.07.002]
3. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491 [PMID: 16678561 DOI: 10.1053/j.gastro.2005.11.061]
4. Burbige EJ. Irritable bowel syndrome: diagnostic approaches in clinical practice. Clin Exp Gastroenterol 2010; 3: 127-137 [PMID: 21694856 DOI: 10.2147/CEG.S12596]
5. Frissora CL, Koch KL. Symptom overlap and comorbidity of irritable bowel syndrome with other conditions. Curr Gastroenterol Rep 2005; 7: 264-271 [PMID: 16042909 DOI: 10.1007/s11894-005-0018-9]
6. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002; 122: 1140-1156 [PMID: 11910364 DOI: 10.1053/gast.2002.32392]
7. Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med 2000; 160: 221-227 [PMID: 10647761 DOI: 10.1001/archinte.160.2.221]
8. Nellesen D, Chawla A, Oh DL, Weissman T, Lavins BJ, Murray CW. Comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation: a review of the literature from the past decade. Postgrad Med 2013; 125: 40-50 [PMID: 23816770 DOI: 10.3810/pgm.2013.03.2640]
9. Spiller R. Clinical update: irritable bowel syndrome. Lancet 2007; 369: 1586-1588 [PMID: 17499587 DOI: 10.1016/S0140-6736(07)60726-0]
10. Barbara G, Cremon C, Carini G, Bellacosa L, Zecchi L, De Giorgio R, Corinaldesi R, Stanghellini V. The immune system in irritable bowel syndrome. J Neurogastroenterol Motil 2011; 17: 349-359 [PMID: 22148103 DOI: 10.5056/jnm.2011.17.4.349]
11. Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics 2006; 24: 21-37 [PMID: 16445300 DOI: 10.2165/00019053-200624010-00002]
12. Nyrop KA, Palsson OS, Levy RL, Von Korff M, Feld AD, Turner MJ, Whitehead WE. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther 2007; 26: 237-248 [PMID: 17593069 DOI: 10.1111/j.1365-2036.2007.03370.x]
13. Whitehead WE, Palsson OS, Levy RR, Feld AD, Turner M, Von Korff M. Comorbidity in irritable bowel syndrome. Am J Gastroenterol 2007; 102: 2767-2776 [PMID: 17900326 DOI: 10.1111/j.1572-0241.2007.01540.x]
14. De Ponti F. Drug development for the irritable bowel syndrome: current challenges and future perspectives. Front Pharmacol 2013; 4: 7 [PMID: 23378837 DOI: 10.3389/fphar.2013.00007]
15. El-Salhy M. Irritable bowel syndrome: diagnosis and pathogenesis. World J Gastroenterol 2012; 18: 5151-5163 [PMID: 23066308 DOI: 10.3748/wjg.v18.i37.5151]
16. Whorwell PJ, McCallum M, Creed FH, Roberts CT. Noncolonic features of irritable bowel syndrome. Gut 1986; 27: 37-40 [PMID: 3949235 DOI: 10.1136/gut.27.1.37]
17. Kalantar JS, Locke GR, Zinsmeister AR, Beighley CM, Talley NJ. Familial aggregation of irritable bowel syndrome: a prospective study. Gut 2003; 52: 1703-1707 [PMID: 14633946 DOI: 10.1136/gut.52.12.1703]
18. Bengtson MB, Rønning T, Vatn MH, Harris JR. Irritable bowel syndrome in twins: genes and environment. Gut 2006; 55: 1754-1759 [PMID: 17008364 DOI: 10.1136/gut.2006.097287]
19. Mohammed I, Cherkas LF, Riley SA, Spector TD, Trudgill NJ. Genetic influences in irritable bowel syndrome: a twin study. Am J Gastroenterol 2005; 100: 1340-1344 [PMID: 15929767 DOI: 10.1111/j.1572-0241.2005.41700.x]
20. Park MI, Camilleri M. Genetics and genotypes in irritable bowel syndrome: implications for diagnosis and treatment. Gastroenterol Clin North Am 2005; 34: 305-317 [PMID: 15862937 DOI: 10.1016/j.gtc.2005.02.009]
21. Barkhordari E, Rezaei N, Ansaripour B, Larki P, Alighardashi M, Ahmadi-Ashtiani HR, Mahmoudi M, Keramati MR, Habibollahi P, Bashashati M, Ebrahimi-Daryani N, Amirzargar AA. Proinflammatory cytokine gene polymorphisms in irritable bowel syndrome. J Clin Immunol 2010; 30: 74-79 [PMID: 19844779 DOI: 10.1007/s10875-009-9342-4]
22. Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003; 52: 91-93 [PMID: 12477767 DOI: 10.1136/gut.52.1.91]
23. Van Kerkhoven LA, Laheij RJ, Jansen JB. Meta-analysis: a functional polymorphism in the gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 979-986 [PMID: 17877505 DOI: 10.1111/j.1365-2036.2007.03453.x]
24. Colucci R, Gambaccini D, Ghisu N, Rossi G, Costa F, Tuccori M, De Bortoli N, Fornai M, Antonioli L, Ricchiuti A, Mumolo MG, Marchi S, Blandizzi C, Bellini M. Influence of the serotonin transporter 5HTTLPR polymorphism on symptom severity in irritable bowel syndrome. PLoS One 2013; 8: e54831 [PMID: 23393559 DOI: 10.1371/journal.pone.0054831]
25. Palsson OS, Drossman DA. Psychiatric and psychological dysfunction in irritable bowel syndrome and the role of psychological treatments. Gastroenterol Clin North Am 2005; 34: 281-303 [PMID: 15862936 DOI: 10.1016/j.gtc.2005.02.004]
26. Halpert A, Drossman D. Biopsychosocial issues in irritable bowel syndrome. J Clin Gastroenterol 2005; 39: 665-669 [PMID: 16082273 DOI: 10.1097/01.mcg.0000174024.81096.44]
27. Drossman DA, Lowman BC. Irritable bowel syndrome: epidemiology, diagnosis and treatment. Clin Gastroenterol 1985; 14: 559-573 [PMID: 3877580]
28. Evans PR, Bennett EJ, Bak YT, Tennant CC, Kellow JE. Jejunal sensorimotor dysfunction in irritable bowel syndrome: clinical and psychosocial features. Gastroenterology 1996; 110: 393-404 [PMID: 8566585 DOI: 10.1053/gast.1996.v110.pm8566585]
29. Kellow JE . Pathophysiology and management of irritable bowel syndrome. Korean J Intern Med 2001; 16: 137-146 [PMID: 11769571]
30. Vassallo MJ, Camilleri M, Phillips SF, Steadman CJ, Talley NJ, Hanson RB, Haddad AC. Colonic tone and motility in patients with irritable bowel syndrome. Mayo Clin Proc 1992; 67: 725-731 [PMID: 1434910 DOI: 10.1016/S0025-6196(12)60796-4]
31. Stivland T, Camilleri M, Vassallo M, Proano M, Rath D, Brown M, Thomforde G, Pemberton J, Phillips S. Scintigraphic measurement of regional gut transit in idiopathic constipation. Gastroenterology 1991; 101: 107-115 [PMID: 2044899]
32. Manabe N, Wong BS, Camilleri M, Burton D, McKinzie S, Zinsmeister AR. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil 2010; 22: 293-e82 [PMID: 20025692 DOI: 10.1111/j.1365-2982.2009.01442.x]
33. Törnblom H, Van Oudenhove L, Sadik R, Abrahamsson H, Tack J, Simrén M. Colonic transit time and IBS symptoms: what's the link? Am J Gastroenterol 2012; 107: 754-760 [PMID: 22334251 DOI: 10.1038/ajg.2012.5]
34. Salvioli B, Serra J, Azpiroz F, Lorenzo C, Aguade S, Castell J, Malagelada JR. Origin of gas retention and symptoms in patients with bloating. Gastroenterology 2005; 128: 574-579 [PMID: 15765392 DOI: 10.1053/j.gastro.2004.12.047]
35. Di Stefano M, Miceli E, Missanelli A, Mazzocchi S, Corazza GR. Meal induced rectosigmoid tone modification: a low caloric meal accurately separates functional and organic gastrointestinal disease patients. Gut 2006; 55: 1409-1414 [PMID: 16434428 DOI: 10.1136/gut.2005.076323]
36. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973; 14: 125-132 [PMID: 4696535 DOI: 10.1136/gut.14.2.125]
37. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012; 303: G775-G785 [PMID: 22837345 DOI: 10.1152/ajpgi.00155.2012]
38. Mayer EA. The neurobiology of stress and gastrointestinal disease. Gut 2000; 47: 861-869 [PMID: 11076888 DOI: 10.1136/gut.47.6.861]
39. Verne GN, Himes NC, Robinson ME, Gopinath KS, Briggs RW, Crosson B, Price DD. Central representation of visceral and cutaneous hypersensitivity in the irritable bowel syndrome. Pain 2003; 103: 99-110 [PMID: 12749964 DOI: 10.1016/S0304-3959(02)00416-5]
40. Delvaux M, Denis P, Allemand H. Sexual abuse is more frequently reported by IBS patients than by patients with organic digestive diseases or controls. Results of a multicentre inquiry. French Club of Digestive Motility. Eur J Gastroenterol Hepatol 1997; 9: 345-352 [PMID: 9160196 DOI: 10.1097/00042737-199704000-00006]
41. Stasi C, Rosselli M, Bellini M, Laffi G, Milani S. Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol 2012; 47: 1177-1185 [PMID: 22766747 DOI: 10.1007/s00535-012-0627-7]
42. Matricon J, Meleine M, Gelot A, Piche T, Dapoigny M, Muller E, Ardid D. Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 2012; 36: 1009-1031 [PMID: 23066886 DOI: 10.1111/apt.12080]
43. Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998; 42: 845-849 [PMID: 9691924 DOI: 10.1136/gut.42.6.845]
44. Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O' Mahony L, O'Mahony S, Shanahan F, Keeling PW. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130: 304-311 [PMID: 16472586 DOI: 10.1053/j.gastro.2005.11.033]
45. Stasi C, Bellini M, Costa F, Mumolo MG, Ricchiuti A, Grosso M, Duranti E, Metelli MR, Gambaccini D, Bianchi L, Di Tanna GL, Laffi G, Taddei S, Marchi S. Neuroendocrine markers and psychological features in patients with irritable bowel syndrome. Int J Colorectal Dis 2013; 28: 1203-1208 [PMID: 23377858 DOI: 10.1007/s00384-013-1646-4]
46. Mertz H. Role of the brain and sensory pathways in gastrointestinal sensory disorders in humans. Gut 2002; 51 Suppl 1: i29-i33 [PMID: 12077061 DOI: 10.1136/gut.51.suppl-1.i29]
47. Mertz H. Review article: visceral hypersensitivity. Aliment Pharmacol Ther 2003; 17: 623-633 [PMID: 12641510 DOI: 10.1046/j.1365-2036.2003.01447.x]
48. Naliboff BD, Berman S, Suyenobu B, Labus JS, Chang L, Stains J, Mandelkern MA, Mayer EA. Longitudinal change in perceptual and brain activation response to visceral stimuli in irritable bowel syndrome patients. Gastroenterology 2006; 131: 352-365 [PMID: 16890589 DOI: 10.1053/j.gastro.2006.05.014]
49. Bellini M, Alduini P, Bassotti G, Bove A, Bocchini R, Sormani MP, Bruzzi P, Pucciani F; Italian Constipation Study Group. Self-perceived normality in defecation habits. Dig Liver Dis 2006; 38: 103-108 [PMID: 16263343]
50. Collins SM. Is the irritable gut an inflamed gut? Scand J Gastroenterol Suppl 1992; 192: 102-105 [PMID: 1439559 DOI: 10.3109/00365529209095988]
51. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20 Suppl 2: 1-9 [PMID: 15335408 DOI: 10.1111/j.1365-2036.2004.02058.x]
52. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-1783 [PMID: 12055584 DOI: 10.1053/gast.2002.33579]
53. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702 [PMID: 14988823 DOI: 10.1053/j.gastro.2003.11.055]
54. Cremon C, Gargano L, Morselli-Labate AM, Santini D, Cogliandro RF, De Giorgio R, Stanghellini V, Corinaldesi R, Barbara G. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392-400 [PMID: 19174797 DOI: 10.1038/ajg.2008.94]
55. Barbara G, Cremon C, Pallotti F, De Giorgio R, Stanghellini V, Corinaldesi R. Postinfectious irritable bowel syndrome. J Pediatr Gastroenterol Nutr 2009; 48 Suppl 2: S95-S97 [PMID: 19300138 DOI: 10.1097/MPG.0b013e3181a15e2e]
56. Begtrup LM, de Muckadell OB, Kjeldsen J, Christensen RD, Jarbøl DE. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome - a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol 2013; 48: 1127-1135 [PMID: 23957590 DOI: 10.3109/00365521.2013.825314]
57. Ohman L, Simrén M. Intestinal microbiota and its role in irritable bowel syndrome (IBS). Curr Gastroenterol Rep 2013; 15: 323 [PMID: 23580243 DOI: 10.1007/s11894-013-0323-7]
58. Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG; Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013; 62: 159-176 [PMID: 22730468 DOI: 10.1136/gutjnl-2012-302167]
59. Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 2004; 53: 1459-1464 [PMID: 15361495 DOI: 10.1136/gut.2003.037697]
60. Zar S, Benson MJ, Kumar D. Food-specific serum IgG4 and IgE titers to common food antigens in irritable bowel syndrome. Am J Gastroenterol 2005; 100: 1550-1557 [PMID: 15984980 DOI: 10.1111/j.1572-0241.2005.41348.x]
61. Biesiekierski JR, Peters SL, Newnham ED, Rosella O, Muir JG, Gibson PR. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013; 145: 320-8.e1-320-8.e3 [PMID: 23648697 DOI: 10.1053/j.gastro.2013.04.051]
62. Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals? Therap Adv Gastroenterol 2012; 5: 261-268 [PMID: 22778791 DOI: 10.1177/1756283X11436241]
63. Quigley EM, Abdel-Hamid H, Barbara G, Bhatia SJ, Boeckxstaens G, De Giorgio R, Delvaux M, Drossman DA, Foxx-Orenstein AE, Guarner F, Gwee KA, Harris LA, Hungin AP, Hunt RH, Kellow JE, Khalif IL, Kruis W, Lindberg G, Olano C, Moraes-Filho JP, Schiller LR, Schmulson M, Simrén M, Tzeuton C. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol 2012; 46: 356-366 [PMID: 22499071 DOI: 10.1097/MCG.0b013e318247157c]
64. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, Whorwell P; Clinical Services Committee of The British Society of Gastroenterology. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56: 1770-1798 [PMID: 17488783 DOI: 10.1136/gut.2007.119446]
65. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32: 920-924 [PMID: 9299672 DOI: 10.3109/00365529709011203]
66. Sperber AD, Drossman DA. Irritable bowel syndrome: a multidimensional disorder cannot be understood or treated from a unidimensional perspective. Therap Adv Gastroenterol 2012; 5: 387-393 [PMID: 23152732 DOI: 10.1177/1756283X12460420]
67. Bellini M, Gemignani A, Gambaccini D, Toti S, Menicucci D, Stasi C, Costa F, Mumolo MG, Ricchiuti A, Bedini R, de Bortoli N, Marchi S. Evaluation of latent links between irritable bowel syndrome and sleep quality. World J Gastroenterol 2011; 17: 5089-5096 [PMID: 22171143 DOI: 10.3748/wjg.v17.i46.5089]
68. World Gastroenterology Organisation . Global guideline. Irritable bowel syndrome: A global perspective, 2009. Available from: URL: http://www.worldgastroenterology.org/irritable-bowel-syndrome.html
69. American College of Gastroenterology Task Force on Irritable Bowel Syndrome; Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 Suppl 1: S1-35 [PMID: 19521341 DOI: 10.1038/ajg.2008.122]
70. Bove A, Pucciani F, Bellini M, Battaglia E, Bocchini R, Altomare DF, Dodi G, Sciaudone G, Falletto E, Piloni V, Gambaccini D, Bove V. Consensus statement AIGO/SICCR: diagnosis and treatment of chronic constipation and obstructed defecation (part I: diagnosis). World J Gastroenterol 2012; 18: 1555-1564 [PMID: 22529683 DOI: 10.3748/wjg.v18.i14.1555]
71. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-2131 [PMID: 12454866 DOI: 10.1053/gast.2002.37095]
72. Wong RK, Drossman DA, Bharucha AE, Rao SS, Wald A, Morris CB, Oxentenko AS, Ravi K, Van Handel DM, Edwards H, Hu Y, Bangdiwala S. The digital rectal examination: a multicenter survey of physicians' and students' perceptions and practice patterns. Am J Gastroenterol 2012; 107: 1157-1163 [PMID: 22858996 DOI: 10.1038/ajg.2012.23]
73. Bijkerk CJ, de Wit NJ, Muris JW, Jones RH, Knottnerus JA, Hoes AW. Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics. Am J Gastroenterol 2003; 98: 122-127 [PMID: 12526947 DOI: 10.1111/j.1572-0241.2003.07158.x]
74. Mangel AW, Hahn BA, Heath AT, Northcutt AR, Kong S, Dukes GE, McSorley D. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res 1998; 26: 76-81 [PMID: 9602985]
75. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997; 11: 395-402 [PMID: 9146781 DOI: 10.1046/j.1365-2036.1997.142318000.x]
76. Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998; 43: 400-411 [PMID: 9512138 DOI: 10.1023/A:1018831127942]
77. Wong E, Guyatt GH, Cook DJ, Griffith LE, Irvine EJ. Development of a questionnaire to measure quality of life in patients with irritable bowel syndrome. Eur J Surg Suppl 1998; (583): 50-56 [PMID: 10027673]
78. Cash BD, Rubenstein JH, Young PE, Gentry A, Nojkov B, Lee D, Andrews AH, Dobhan R, Chey WD. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology 2011; 141: 1187-1193 [PMID: 21762658 DOI: 10.1053/j.gastro.2011.06.084]
79. Pavlidis P, Chedgy FJ, Tibble JA. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care. Scand J Gastroenterol 2013; 48: 1048-1054 [PMID: 23883068 DOI: 10.3109/00365521.2013.816771]
80. Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, Sterpi C, Marchi S, Maltinti G. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003; 35: 642-647 [PMID: 14563186 DOI: 10.1016/S1590-8658(03)00381-5]
81. Chang L, Adeyemo M, Karagiannides I, Videlock EJ, Bowe C, Shih W, Presson AP, Yuan PQ, Cortina G, Gong H, Singh S, Licudine A, Mayer M, Tache Y, Pothoulakis C, Mayer EA. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 2012; 107: 262-272 [PMID: 22158028 DOI: 10.1038/ajg.2011.423]
82. Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 2010; 32: 144-158 [PMID: 20412064 DOI: 10.1111/j.1365-2036.2010.04328]
83. Costa F, Mumolo MG, Marchi S, Bellini M. Differential diagnosis between functional and organic intestinal disorders: is there a role for non-invasive tests? World J Gastroenterol 2007; 13: 219-223 [PMID: 17226899]
84. Spiller RC, Thompson WG. Bowel disorders. Am J Gastroenterol 2010; 105: 775-785 [PMID: 20372130 DOI: 10.1038/ajg.2010.69]
85. Lesbros-Pantoflickova D, Michetti P, Fried M, Beglinger C, Blum AL. Meta-analysis: The treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20: 1253-1269 [PMID: 15606387 DOI: 10.1111/j.1365-2036.2004.02267.x]
86. Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective. Aliment Pharmacol Ther 2006; 24: 183-205 [PMID: 16842448 DOI: 10.1111/j.1365-2036.2006.02938.x]
87. Staudacher HM, Lomer MC, Anderson JL, Barrett JS, Muir JG, Irving PM, Whelan K. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 2012; 142: 1510-1518 [PMID: 22739368 DOI: 10.3945/jn.112.159285]
88. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313 [PMID: 19008265 DOI: 10.1136/bmj.a2313]
89. Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23: 191-196 [PMID: 16393297 DOI: 10.1111/j.1365-2036.2006.02705.x]
90. Bharucha AE, Pemberton JH, Locke GR. American Gastroenterological Association technical review on constipation. Gastroenterology 2013; 144: 218-238 [PMID: 23261065 DOI: 10.1053/j.gastro.2012.10.028]
91. Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, Ueno R. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29: 329-341 [PMID: 19006537]
92. Chey WD, Drossman DA, Johanson JF, Scott C, Panas RM, Ueno R. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2012; 35: 587-599 [PMID: 22251419 DOI: 10.1111/j.1365-2036.2011.04983.x]
93. Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE, Shao JZ, Eng P, Fox SM, Schneier HA, Kurtz CB, Johnston JM. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107: 1714-1724; quiz p.1725 [PMID: 22986440 DOI: 10.1038/ajg.2012.255]
94. Quigley EM, Tack J, Chey WD, Rao SS, Fortea J, Falques M, Diaz C, Shiff SJ, Currie MG, Johnston JM. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther 2013; 37: 49-61 [PMID: 23116208 DOI: 10.1111/apt.12123]
95. Lavö B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome - a double-blind placebo controlled study. Scand J Gastroenterol Suppl 1987; 130: 77-80 [PMID: 3306903 DOI: 10.3109/00365528709091003]
96. Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G, Almenoff JS, Covington PS. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology 2013; 145: 329-338. e1 [PMID: 23583433 DOI: 10.1053/j.gastro.2013.04.006]
97. Chang L, Lacy BE, Spiegel BM. An Evidence-based Approach to Therapy in IBS-D: A Case Study Compendium. Gastroenterol Hepatol (N Y) 2010; 6: 1-12 [PMID: 22570639]
98. Chiba T, Yamamoto K, Sato S, Suzuki K. Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol 2013; 6: 123-128 [PMID: 23922505 DOI: 10.2147/CEG.S32721]
99. Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009; 30: 707-717 [PMID: 19570102 DOI: 10.1111/j.1365-2036.2009.04081.x]
100. Bafutto M, Almeida JR, Leite NV, Oliveira EC, Gabriel-Neto S, Rezende-Filho J. Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine. Arq Gastroenterol 2011; 48: 36-40 [PMID: 21537540 DOI: 10.1590/S0004-28032011000100008]
101. Leighton MP, Lam C, Mehta S, Spiller RC. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial. Trials 2013; 14: 10 [PMID: 23302220 DOI: 10.1186/1745-6215-14-10]
102. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32 [PMID: 21208106 DOI: 10.1056/NEJMoa1004409]
103. Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 28-35; quiz 36 [PMID: 22045120 DOI: 10.1038/ajg.2011.355]
104. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010; 59: 325-332 [PMID: 19091823 DOI: 10.1136/gut.2008.167270]
105. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-378 [PMID: 19001059 DOI: 10.1136/gut.2008.163162]
106. Lindfors P, Unge P, Arvidsson P, Nyhlin H, Björnsson E, Abrahamsson H, Simrén M. Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials. Am J Gastroenterol 2012; 107: 276-285 [PMID: 21971535 DOI: 10.1038/ajg.2011.340]
107. Lowén MB, Mayer EA, Sjöberg M, Tillisch K, Naliboff B, Labus J, Lundberg P, Ström M, Engström M, Walter SA. Effect of hypnotherapy and educational intervention on brain response to visceral stimulus in the irritable bowel syndrome. Aliment Pharmacol Ther 2013; 37: 1184-1197 [PMID: 23617618 DOI: 10.1111/apt.12319]
108. Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multicentre trial. Aliment Pharmacol Ther 2004; 19: 271-279 [PMID: 14984373 DOI: 10.1111/j.1365-2036.2004.01859.x]
109. Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 1998; 280: 1585-1589 [PMID: 9820260 DOI: 10.1001/jama.280.18.1585]
110. Lim B, Manheimer E, Lao L, Ziea E, Wisniewski J, Liu J, Berman B. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006; (4) : CD005111 [PMID: 17054239]
111. MacPherson H, Tilbrook H, Bland JM, Bloor K, Brabyn S, Cox H, Kang'ombe AR, Man MS, Stuardi T, Torgerson D, Watt I, Whorwell P. Acupuncture for irritable bowel syndrome: primary care based pragmatic randomised controlled trial. BMC Gastroenterol 2012; 12: 150 [PMID: 23095376 DOI: 10.1186/1471-230X-12-150]